BCM
FATE icon

BlueCrest Capital Management’s Fate Therapeutics FATE Stock Holding History

BlueCrest Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-24,570
Closed -$400K – 1043
2018
Q3 		$400K Buy
+24,570
New +$291K 0.01% 877
2017
Q2 		– Sell
-17,728
Closed -$81K – 964
2017
Q1 		$81K Buy
+17,728
New +$64.9K ﹤0.01% 685

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlueCrest Capital Management's FATE Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Fate Therapeutics (FATE) in Q4 2018, closing a stake of 24,570 shares — an estimated $400K sold.

BlueCrest Capital Management first reported a position in FATE in Q1 2017 and held it in 2 quarters. The position peaked at $400K in Q3 2018. 122 funds tracked by Wall St. Rank hold FATE as of Q4 2018.

  • BlueCrest Capital Management reported no remaining Fate Therapeutics position as of Q4 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 24,570 Fate Therapeutics shares in Q4 2018, an estimated $400K.
  • BlueCrest Capital Management first reported a position in Fate Therapeutics in Q1 2017 and held it in 2 quarters.
  • BlueCrest Capital Management's Fate Therapeutics position peaked at $400K in Q3 2018.
  • 122 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.